Harvard Bioscience (HBIO) EBT Margin (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of EBT Margin data on file, last reported at 15.93% in Q1 2026.

• On a quarterly basis, EBT Margin rose 21734.0% year-over-year to 15.93% in Q1 2026; TTM through Mar 2026 was 11.57%, a 5186.0% increase from a year earlier, with the FY2025 full-year figure at 66.3%, down 5391.0% from the prior year.
• EBT Margin for Q1 2026 stood at 15.93%, down from 13.5% in the prior quarter.
• Over the last five years, EBT Margin for HBIO reached as high as 11.71% in Q2 2022 and fell as low as 233.28% in Q1 2025.
• Historically, EBT Margin has averaged 21.91% across 5 years, with a median of 11.02% in 2025.
• Across the five-year window, EBT Margin slumped 21499 bps in 2025 and surged 21734 bps in 2026, its largest moves.
• Year by year, EBT Margin stood at 3.14% in 2022, then retreated by 25 bps to 3.92% in 2023, then surged by 161 bps to 2.4% in 2024, then plunged by 662 bps to 13.5% in 2025, then decreased by 18 bps to 15.93% in 2026.
• Per Business Quant data, the three most recent EBT Margin figures were 15.93% in Q1 2026, 13.5% in Q4 2025, and 5.51% in Q3 2025.